GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of ...

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

Using microneedle arrays developed at Carnegie Melon, microdosed with a known chemotherapeutic agent delivered directly to ...

Agentic AI refers to AI systems that add layers of reason and autonomy. They act as largely independent agents that are ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...